David A. Siegel 4 D Molecular Therapeutics, Inc. Call Options Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding FDMT
# of Institutions
144Shares Held
57.7MCall Options Held
137KPut Options Held
111K-
Bvf Inc San Francisco, CA7.38MShares$56.3 Million2.54% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.1MShares$38.8 Million0.77% of portfolio
-
Black Rock Inc. New York, NY4.9MShares$37.3 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY4.4MShares$33.5 Million4.93% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.1MShares$31.2 Million1.63% of portfolio
About 4D Molecular Therapeutics, Inc.
- Ticker FDMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 32,382,400
- Market Cap $247M
- Description
- 4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical tr...